Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Eliem Therapeutics, Inc. (ELYM)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and their focus is on restoring homeostasis. They are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Their two lead clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSR, commonly referred to as sciatica). ETX-810 is being evaluated in two Phase 2a clinical trials that are expected to report topline data in the first half of 2022. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for the treatment of major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS), the most common type of seizure in people with epilepsy. They plan to initiate two Phase 2a clinical trials for ETX-155 in patients with MDD and PMD which are expected to report topline data in the first half of 2023, and a Phase 1b clinical trial in patients with photosensitive epilepsy that is expected to report topline data by the first half of 2022.
Industry
Pharmaceutical Preparations
CEO CFO
Robert Azelby Erin M. Lavelle
Employees Founded
25 2018

Contacts

Address: 23515 Ne Novelty Hill Road, Suite B221 #125, Redmond, Wa 98053, Us

Telephone: (425) 276-2300.

Web page: http://www.eliemtx.com

IPO information

First Trade Date 8/10/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $17.00-$19.00
Share prices ($)

Shares & Volumes

Shares Initial (MM) 4.5
Shares Revised (MM) 6.4
Expected offer amount (MM) $81
Realized offer amount(MM) $80

Financial Data (last reporting year)

Market Cap (MM) $422.7
Revenues (MM) $0
Net Income (Loss) (MM) $-40.3

Voting

What do you think will happen with the ELYM share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: SVB Leerink

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
SVB Leerink/ Evercore ISI/ Stifel/ Guggenheim Securities
CO-Managers

Sector: Healthcare

Tweets about $ELYM

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats